Cargando…

Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study

BACKGROUND: Ketorolac is a potent nonsteroidal anti-inflammatory drug that has valuable analgesic properties but also a hypothetical risk of increased bleeding due to inhibition of platelet activation. The clinical significance of this risk, however, is unclear when it is used after reduction mammap...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkho, Jouseph O., Li, Yu Kit, Duku, Eric, Thoma, Achilleas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908486/
https://www.ncbi.nlm.nih.gov/pubmed/29707458
http://dx.doi.org/10.1097/GOX.0000000000001699
_version_ 1783315721800908800
author Barkho, Jouseph O.
Li, Yu Kit
Duku, Eric
Thoma, Achilleas
author_facet Barkho, Jouseph O.
Li, Yu Kit
Duku, Eric
Thoma, Achilleas
author_sort Barkho, Jouseph O.
collection PubMed
description BACKGROUND: Ketorolac is a potent nonsteroidal anti-inflammatory drug that has valuable analgesic properties but also a hypothetical risk of increased bleeding due to inhibition of platelet activation. The clinical significance of this risk, however, is unclear when it is used after reduction mammaplasty. Our study objective was to therefore examine the association between ketorolac exposure and hematoma occurrence after breast reduction surgery. We hypothesized that there was no association between ketorolac exposure and hematoma occurrence in breast reduction surgery. METHODS: A case-control design was used. Data from charts of all reduction mammaplasties that developed hematomas requiring surgical evacuation (cases) at our university-based hospitals were retrieved and matched to data from charts of reduction mammaplasty patients who did not indicate this complication (controls). Matching occurred in a 1:1 ratio based on 4 criteria: age, body mass index, institution, and preexisting hypertension. Charts were reviewed for retrospective information on exposure to ketorolac. Odds ratio (OR) was calculated with an OR > 1 favoring an association. RESULTS: From 2002 to 2016, 40 cases of hematoma met inclusion criteria and were matched with 40 controls (N = 80). Cases had a significantly lower body mass index than controls; however, the other baseline patient demographics were similar between the 2 groups. There was an association between hematoma formation and exposure to ketorolac (OR, 2.4; 95% confidence interval, 0.8–7.4; P = 0.114) and a trend for greater risk of hematoma formation, although this was not statistically significant. CONCLUSIONS: Based on this level 3 evidence, there appears to be an association between perioperative ketorolac exposure and hematoma after breast reduction surgery, but it was not statistically significant. Although this study was adequately powered, the OR of 2.4 was associated with a wide confidence interval. A larger sample size may increase the precision of the results and may also make the association definitive.
format Online
Article
Text
id pubmed-5908486
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59084862018-04-27 Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study Barkho, Jouseph O. Li, Yu Kit Duku, Eric Thoma, Achilleas Plast Reconstr Surg Glob Open Original Article BACKGROUND: Ketorolac is a potent nonsteroidal anti-inflammatory drug that has valuable analgesic properties but also a hypothetical risk of increased bleeding due to inhibition of platelet activation. The clinical significance of this risk, however, is unclear when it is used after reduction mammaplasty. Our study objective was to therefore examine the association between ketorolac exposure and hematoma occurrence after breast reduction surgery. We hypothesized that there was no association between ketorolac exposure and hematoma occurrence in breast reduction surgery. METHODS: A case-control design was used. Data from charts of all reduction mammaplasties that developed hematomas requiring surgical evacuation (cases) at our university-based hospitals were retrieved and matched to data from charts of reduction mammaplasty patients who did not indicate this complication (controls). Matching occurred in a 1:1 ratio based on 4 criteria: age, body mass index, institution, and preexisting hypertension. Charts were reviewed for retrospective information on exposure to ketorolac. Odds ratio (OR) was calculated with an OR > 1 favoring an association. RESULTS: From 2002 to 2016, 40 cases of hematoma met inclusion criteria and were matched with 40 controls (N = 80). Cases had a significantly lower body mass index than controls; however, the other baseline patient demographics were similar between the 2 groups. There was an association between hematoma formation and exposure to ketorolac (OR, 2.4; 95% confidence interval, 0.8–7.4; P = 0.114) and a trend for greater risk of hematoma formation, although this was not statistically significant. CONCLUSIONS: Based on this level 3 evidence, there appears to be an association between perioperative ketorolac exposure and hematoma after breast reduction surgery, but it was not statistically significant. Although this study was adequately powered, the OR of 2.4 was associated with a wide confidence interval. A larger sample size may increase the precision of the results and may also make the association definitive. Wolters Kluwer Health 2018-03-19 /pmc/articles/PMC5908486/ /pubmed/29707458 http://dx.doi.org/10.1097/GOX.0000000000001699 Text en Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Barkho, Jouseph O.
Li, Yu Kit
Duku, Eric
Thoma, Achilleas
Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title_full Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title_fullStr Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title_full_unstemmed Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title_short Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study
title_sort ketorolac may increase hematoma risk in reduction mammaplasty: a case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908486/
https://www.ncbi.nlm.nih.gov/pubmed/29707458
http://dx.doi.org/10.1097/GOX.0000000000001699
work_keys_str_mv AT barkhojousepho ketorolacmayincreasehematomariskinreductionmammaplastyacasecontrolstudy
AT liyukit ketorolacmayincreasehematomariskinreductionmammaplastyacasecontrolstudy
AT dukueric ketorolacmayincreasehematomariskinreductionmammaplastyacasecontrolstudy
AT thomaachilleas ketorolacmayincreasehematomariskinreductionmammaplastyacasecontrolstudy